Legal status CA: Schedule IV CAS Number 39243-02-2 UNII 8LH16383PK Pubchem 12562545 ChemSpider ID 15417688 | Biological half-life 17 hours PubChem CID 12562545 Molar mass 354.204 g/mol ChEMBL ID 3246831 | |
 | ||
Routes of
administration Oral, Sublingual, rectal | ||
Pyrazolam is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s, and subsequently "rediscovered" and sold as a designer drug starting in 2012.
Pyrazolam has structural similarities to alprazolam and bromazepam. Unlike other benzodiazepines, pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine. It is most selective for the α2 and α3 subtypes of the GABAA receptor.
References
Pyrazolam Wikipedia(Text) CC BY-SA